Related Experiment Video

Updated: Jun 8, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation

Wei Zhao1, Tao Zhang, Bingqian Qu

  • 1State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China.

Anti-Cancer Drugs
|October 1, 2010
PubMed

Insights

Sorafenib, a multikinase inhibitor, induces apoptosis in acute myeloid leukemia (AML) by inhibiting Signal transducer and activator of transcription 3 (STAT3) phosphorylation via Src kinase activity. This targeted approach offers a potential new treatment strategy for AML.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Constitutive activation of Signal transducer and activator of transcription 3 (STAT3) is common in acute myeloid leukemia (AML), promoting cell survival.
  • Inhibiting STAT3 activity has shown promise in inducing apoptosis in AML cells.

Purpose of the Study:

  • To investigate if sorafenib, a known multikinase inhibitor, can inhibit STAT3 signaling pathways.
  • To evaluate the efficacy of sorafenib in treating human AML by targeting STAT3.

Main Methods:

  • Assessing sorafenib's effects on proliferation and apoptosis in human AML cell lines (HL60).
  • Measuring STAT3 phosphorylation, DNA-binding activity, and expression of apoptosis-related proteins (Mcl-1, Bcl-2).
  • Investigating the role of Src kinase in sorafenib-induced STAT3 inhibition using kinase assays and co-immunoprecipitation.

Main Results:

  • Sorafenib inhibited HL60 cell proliferation and induced apoptosis.
  • Sorafenib reduced STAT3 phosphorylation, DNA-binding activity, and expression of Mcl-1 and Bcl-2.
  • Sorafenib suppressed Src kinase activity, indicating it blocks STAT3 phosphorylation through Src kinase inhibition.

Conclusions:

  • Sorafenib effectively inhibits Src kinase-mediated STAT3 phosphorylation in AML cells.
  • By decreasing Mcl-1 and Bcl-2 expression, sorafenib promotes apoptosis in HL60 cells.
  • These findings support sorafenib as a potential therapeutic agent for human AML.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...